Clinical Trials | October 03, 2023
Zydus announces IND clearance of a novel Anti-PCSK9 candidate
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Subscribe To Our Newsletter & Stay Updated
